Vaxart Balance Sheet Health
Financial Health criteria checks 6/6
Vaxart has a total shareholder equity of $57.8M and total debt of $6.4M, which brings its debt-to-equity ratio to 11.1%. Its total assets and total liabilities are $91.8M and $34.0M respectively.
Key information
11.1%
Debt to equity ratio
US$6.43m
Debt
| Interest coverage ratio | n/a |
| Cash | US$39.71m |
| Equity | US$57.81m |
| Total liabilities | US$34.03m |
| Total assets | US$91.83m |
Recent financial health updates
Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely
Nov 08
Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely
Jun 30Companies Like Vaxart (NASDAQ:VXRT) Are In A Position To Invest In Growth
Aug 25We're Hopeful That Vaxart (NASDAQ:VXRT) Will Use Its Cash Wisely
May 11Recent updates
Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely
Nov 08Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely
Jun 30Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis
Sep 09Ray Stapleton joins Vaxart as CTO
Aug 31Vaxart shareholders approve proposal to increase number of shares
Aug 05Vaxart continues to lobby shareholders to vote to increase number of shares
Jul 29Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2
Jul 20Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success
Jul 07Vaxart: A Unique Vaccine Concern
Jun 14Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform
Feb 26Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow
Dec 09Vaxart: Differentiated Covid Oral Route Remains Viable
Nov 16Vaxart: A Close Look At Their COVID-19 Oral Tablet Vaccine Program
Oct 30Vaxart: An Update
Oct 02Companies Like Vaxart (NASDAQ:VXRT) Are In A Position To Invest In Growth
Aug 25Vaxart: World's First Oral COVID Vaccine In Development
Jul 25FDA is set to decline new emergency use authorizations for COVID-19 vaccines
May 26We're Hopeful That Vaxart (NASDAQ:VXRT) Will Use Its Cash Wisely
May 11Enrollment underway in Vaxart's early-stage norovirus trial in elderly population
May 07Vaxart EPS misses by $0.04, misses on revenue
May 03Plucky Underdog Vaxart Still Banging Drum For Oral Vaccination
Apr 30Vaxart is soaring on more than 10 times the two-month average volume
Apr 27Shareholders Are Thrilled That The Vaxart (NASDAQ:VXRT) Share Price Increased 231%
Mar 03Financial Position Analysis
Short Term Liabilities: VXRT's short term assets ($45.5M) exceed its short term liabilities ($13.7M).
Long Term Liabilities: VXRT's short term assets ($45.5M) exceed its long term liabilities ($20.3M).
Debt to Equity History and Analysis
Debt Level: VXRT has more cash than its total debt.
Reducing Debt: VXRT's debt to equity ratio has reduced from 190% to 11.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VXRT has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: VXRT is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.